Floatz logo

Tarlatamab

Medullary Thyroid Gland Carcinoma

University of Arizonamonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Medullary Thyroid Gland Carcinoma cohort.

Asset / SponsorPhaseRating
Cabozantinib
National Cancer Institute (NCI)
Phase 2B
Selpercatinib
Eli Lilly and Company
Phase 2B
Oxodotreotide
M.D. Anderson Cancer Center
Phase 2CCC
Everolimus
National Cancer Institute (NCI)
Phase 1CCC
Pralsetinib, Trans-
Hoffmann-La Roche
Phase 1/2CCC

View all 34 →

Same molecule, other indications

Tarlatamab is also rated in:

small cell lung carcinomaActive
BB
Indicative · Phase 3
65 / 100
View asset →
neuroendocrine carcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →
prostate neuroendocrine neoplasmActive
B
Indicative · Phase 2
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →